Martin Hutchings, MD, PhD and Robert Marcus, MA, FRCP, FRCPath
In this episode, “Novel Therapies for Indolent B-Cell Lymphomas”, Martin Hutchings, MD, PhD and Robert Marcus, MA, FRCP, FRCPath offer insights on current controversies.
Targeted agents and new strategies are changing paradigms, along with improved patient outcomes. For advanced-stage follicular lymphoma (FL), clinical questions include patient selection for rituximab maintenance to potentially prolong progression-free survival, and the value of obinutuzumab as part of first line therapy. Another advance in FL is the mounting data in support of combined modality therapy for limited-stage disease.